Vital signs

For "More Clarity in Cardiovascular Imaging": Ziehm Imaging Presents Mobile CathLab and CT Image Fusion with 30 kW Generator at RSNA 2021 in Chicago

Sunday, November 28, 2021 - 12:00pm

NUREMBERG, Germany, Nov. 28, 2021 /PRNewswire/ --At this year's RSNA in Chicago, Ziehm Imaging will present a product range consisting of mobile C-arms and innovative imaging systems.

Key Points: 
  • NUREMBERG, Germany, Nov. 28, 2021 /PRNewswire/ --At this year's RSNA in Chicago, Ziehm Imaging will present a product range consisting of mobile C-arms and innovative imaging systems.
  • Earlier this year, Ziehm Imaging introduced the most powerful generator for mobile C-arms for its motorized RFD series and CMOSline flat panel detector.
  • The mobile CathLab is built on the Ziehm Vision RFD Hybrid Edition Cardio, a powerful fully motorized C-arm for cardiovascular interventions.
  • Together with the 30 kW generator, the mobile CathLab is the perfect solution for challenging cardiology procedures and the cost-effective treatment of coronary indications.

Reliq Health Technologies, Inc. Announces Contracts with Two New Clients in the US, Expansion of iUGO Platform for Hospice Care

Wednesday, November 24, 2021 - 8:01am

These two contracts will add over 1,000 new Medicare patients to our platform at an average revenue of $65 USD per patient per month.

Key Points: 
  • These two contracts will add over 1,000 new Medicare patients to our platform at an average revenue of $65 USD per patient per month.
  • We are also very pleased to announce that we have expanded our Hospice care solution to leverage features from both the iUGO Care and iUGO Home modules.
  • Reliqs powerful iUGO Care platform supports care coordination and community-based virtual healthcare.
  • iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery.

Smart-City Driverless-Vehicle Pilot Project to Enhance Mobility and Healthcare in Kamakura & Fujisawa Areas

Wednesday, November 24, 2021 - 3:27am

Recently, our partnership joined forces with four other interests to commence a pilot project that will combine autonomous-driving technologies and healthcare services in Shonan Health Innovation Park (Shonan iPark).

Key Points: 
  • Recently, our partnership joined forces with four other interests to commence a pilot project that will combine autonomous-driving technologies and healthcare services in Shonan Health Innovation Park (Shonan iPark).
  • Along with Shonan iPark, our other partners on this project are Tokushukai Shonan Kamakura General Hospital (Kamakura General), Macnica, Inc. and Mitsubishi Electric Corporation.
  • Recently, our partnership joined forces with four other interests to commence a pilot project that will combine autonomous-driving technologies and healthcare services in Shonan Health Innovation Park (Shonan iPark).
  • Along with Shonan iPark, our other partners on this project are Tokushukai Shonan Kamakura General Hospital (Kamakura General), Macnica, Inc. and Mitsubishi Electric Corporation.

Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis

Thursday, November 18, 2021 - 9:02pm

SAN DIEGO and TAICANG, SUZHOU, China , Nov. 18, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported positive topline results from the global Phase 2 clinical trial of CBP-201 administered subcutaneously (SC) to adult patients with moderate-to-severe atopic dermatitis (AD) (NCT04444752).

Key Points: 
  • Finally, there were a low reported incidence of injection site reactions (1.8%) and conjunctivitis (3.5%) in patients receiving CBP-201.
  • We are very pleased to have successfully completed this trial on schedule despite the challenges of the COVID-19 pandemic.
  • The Company intends to hold a conference call to discuss the detailed trial results from this global Phase 2 clinical trial by the end of January 2022, following the completion of further analyses.
  • Connect Biopharma cautions that statements included in this press release that are not a description of historical facts are forward-looking statements.

RenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product Line

Monday, November 22, 2021 - 2:00pm

The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders.

Key Points: 
  • The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders.
  • The management team has been based in Asia and has been investing in and advising entrepreneurs for over 20 years.
  • The company's first product, Clarity RMS, provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics.
  • RenalSense's next-generation products will provide additional real-time parameters and expanded diagnostic capabilities to further improve critical care management in the ICU and peri-operative setting.

RenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product Line

Monday, November 22, 2021 - 2:00pm

The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders.

Key Points: 
  • The Series A round was led by BlueRed Partners Fund (Singapore) and includes several large healthcare-focused family offices as well as existing shareholders.
  • The management team has been based in Asia and has been investing in and advising entrepreneurs for over 20 years.
  • The company's first product, Clarity RMS, provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics.
  • RenalSense's next-generation products will provide additional real-time parameters and expanded diagnostic capabilities to further improve critical care management in the ICU and peri-operative setting.

Joerns Healthcare and BioIntelliSense Announce North American Partnership to Expand Access to Innovative, Medical Grade Wearable Devices for Continuous Remote Monitoring, Enabling Patient Care Anywhere

Tuesday, November 16, 2021 - 3:00pm

This collaboration strengthens Joerns Healthcares proven leadership and extensive reach, with BioIntelliSenses continuous remote monitoring devices and data services, to optimize care delivery across care settings.

Key Points: 
  • This collaboration strengthens Joerns Healthcares proven leadership and extensive reach, with BioIntelliSenses continuous remote monitoring devices and data services, to optimize care delivery across care settings.
  • The discreet device works across care settings and provides personalized clinical intelligence in near real-time to allow for proactive interventions and continuous care models.
  • Named a 2021 CES and MedTech Breakthrough Awardee, BioIntelliSense has clearly set a new and novel standard for remote patient monitoring technology.
  • Joerns is excited to partner with BioIntelliSense to bring this trailblazing technology forward, said Doug Ferguson, chief strategy officer for Joerns Healthcare.

Joerns Healthcare and BioIntelliSense Announce North American Partnership to Expand Access to Innovative, Medical Grade Wearable Devices for Continuous Remote Monitoring, Enabling Patient Care Anywhere

Tuesday, November 16, 2021 - 3:00pm

BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM).

Key Points: 
  • BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM).
  • The FDA-cleared BioSticker and medical grade BioButton devices make remote monitoring and early detection simple.
  • Through the platform's advanced analytics, clinicians will now have access to high-resolution patient trending and reporting to enable medical grade care from in the hospital to the home.
  • Joerns Healthcare is a healthcare technology and equipment services company focused on driving the transformation of care nationally across the post-acute continuum.

USA Equities Corp. Announces Third Quarter 2021 Financial Results And Conversion of Secured Convertible Promissory Note

Tuesday, November 16, 2021 - 12:30pm

West Palm Beach, FL, Nov. 16, 2021 (GLOBE NEWSWIRE) -- USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, today announced financial results for the three and nine month periods ended September 30, 2021.

Key Points: 
  • West Palm Beach, FL, Nov. 16, 2021 (GLOBE NEWSWIRE) -- USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, today announced financial results for the three and nine month periods ended September 30, 2021.
  • Total revenues for the nine months ended September 30, 2021 was $1,084,436, compared to $0 revenues in the comparable period of 2020.
  • The Company generated gross profit of $157,086, or a gross margin of approximately 48% in the third quarter 2021.
  • USA Equities Corp. (OTCQB: USAQ) is a medical device company providing digital medicine solutions and point of care diagnostic tests to primary care physicians.

Vizsafe Partners with T-Mobile to provide Health Screening and Health Pass Verification Solutions at Facilities Across the U.S.

Monday, November 15, 2021 - 2:00pm

BOSTON, Nov. 15, 2021 /PRNewswire-PRWeb/ --Vizsafe, Inc. today announced it has selected T-Mobile as the preferred wireless provider to connect its Health Screening and Health Pass Verification solutions over the nation's largest, fastest and most reliable 5G network.

Key Points: 
  • BOSTON, Nov. 15, 2021 /PRNewswire-PRWeb/ --Vizsafe, Inc. today announced it has selected T-Mobile as the preferred wireless provider to connect its Health Screening and Health Pass Verification solutions over the nation's largest, fastest and most reliable 5G network.
  • Vizsafe has also joined the T-Mobile for Business Partner Program to provide their health, safety and security solutions to enterprise customers.
  • Health Pass Verification Tablets - Validates testing, vaccination credentials and SMART Health Cards for intelligent access control.
  • Vizsafe, Inc. is a leading provider of health, safety and security solutions, delivering its patented Geoaware intelligence dashboard with location-powered mobile apps, touchless AI-driven health screening, real-time communications and incident manangement.